Clinical trial registry record

REMAP Trial for Optimizing Surgical Outcomes at UPMC

A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Terminated. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Terminated.
Evidence
Registered phase 3 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated June 18, 2024.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT03861767
Last registry update
June 18, 2024
Status
Terminated
Phase
Phase 3
Sponsor
Matthew Neal MD
Enrollment
302
Countries
United States
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Terminated. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 3
Study design
RANDOMIZED · PARALLEL · TREATMENT · TRIPLE
Evidence population
Human clinical study registration
Participants
302
Population
ALL · 18 Years
Duration
2019-04-15 to 2022-09-23
Intervention
Metformin ER; Placebo
Comparator
SPRY: Placebo
Outcomes measured
Hospital Free Days (HFD) — Day 90 from the date of the elective surgical procedure; Incidence of ICU Admission After Surgery — Participants will be followed for the duration of their hospital admission,…; Incidence and Total Number of Reoperation/Reintervention — Day 90 from the date of the elective surgical procedure; Venous Thromboembolic Events Including Deep Vein Thrombosis and Pulmonary Embolism — Day 90 from the date of the electi…; Number of Participants With Surgical Site Infection — Day 30 from the date of the elective surgical procedure; Number of Participants With Surgical Site Occurrence — Day 30 from the date of the elective surgical procedure; Organ Failure Free Days — Day 30 from the date of the elective surgical procedure; Hospital Length of Stay (LOS) — Participants will be followed for the duration of their hospital admission, estimated t…; ICU (Intensive Care Unit) Length of Stay (LOS) — Participants will be followed for the duration of their hospital admis…; Mortality — Day 90 from the date of the elective surgical procedure; Hospital Readmission Rate — Day 90 from the date of the elective surgical procedure; Gastrointestinal Intolerance — From enrollment to day 90 after surgery; SAE (Serious Adverse Event) as Defined in Core Protocol (Mild, Moderate, Severe, Life Threatening/Disabling; Adjudicate…; Discharge Disposition — Participants will be followed for the duration of their hospital admission, estimated to be 2-4…; In Hospital Mortality — Participants will be followed for the duration of their hospital admission, estimated to be 2-4…
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 3A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Metformin · 100%Abstract contains controlled term: metformin. Source terminology contains: metformin. Abstract supplies longevity context: older adult. Study type is explicitly identified as INTERVENTIONAL.

Automated source check 100% · update recency 65%. These figures help sort records; they are not medical ratings.

metformin
Open primary sourceExport JSON